

# Martin Hälsmann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1410690/publications.pdf>

Version: 2024-02-01

92  
papers

3,148  
citations

257450

24  
h-index

168389

53  
g-index

99  
all docs

99  
docs citations

99  
times ranked

4399  
citing authors

#	ARTICLE	IF	CITATIONS
1	Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 1505-1535.	7.1	555
2	Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. <i>Journal of the American College of Cardiology</i> , 1996, 27, 633-641.	2.8	324
3	Refining the prognostic impact of functional mitral regurgitation in chronic heart failure. <i>European Heart Journal</i> , 2018, 39, 39-46.	2.2	261
4	Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. <i>Heart</i> , 2015, 101, 1874-1880.	2.9	181
5	Muscle strength as a predictor of long-term survival in severe congestive heart failure. <i>European Journal of Heart Failure</i> , 2004, 6, 101-107.	7.1	149
6	Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume. <i>European Heart Journal</i> , 2008, 29, 2343-2350.	2.2	113
7	Natural History of Functional Tricuspid Regurgitation. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 389-397.	5.3	102
8	A Unifying Concept for the Quantitative Assessment of Secondary Mitral Regurgitation. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2506-2517.	2.8	86
9	Prognostic value of plasma midregional proadrenomedullin and C-terminal endothelin-1 in chronic heart failure outpatients. <i>European Journal of Heart Failure</i> , 2009, 11, 361-366.	7.1	78
10	Low- and High-renin Heart Failure Phenotypes with Clinical Implications. <i>Clinical Chemistry</i> , 2018, 64, 597-608.	3.2	52
11	Circulating bile acids predict outcome in critically ill patients. <i>Annals of Intensive Care</i> , 2017, 7, 48.	4.6	49
12	Interleukin-6 and B-type natriuretic peptide are independent predictors for worsening of heart failure in patients with progressive congestive heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2004, 23, 839-844.	0.6	46
13	Secondary valve regurgitation in patients with heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, and heart failure with reduced ejection fraction. <i>European Heart Journal</i> , 2020, 41, 2799-2810.	2.2	45
14	Fibroblast Growth Factor 23 Is an Independent and Specific Predictor of Mortality in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2015, 8, 1059-1067.	3.9	42
15	Evolution of secondary mitral regurgitation. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 622-629.	1.2	40
16	Soluble Urokinase-Type Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 268-277.	4.1	37
17	Endothelial Markers May Link Kidney Function to Cardiovascular Events in Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 1890-1895.	8.6	35
18	Sublingual functional capillary rarefaction in chronic heart failure. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12869.	3.4	34

#	ARTICLE	IF	CITATIONS
19	Influence of age and in-patient care on prescription rate and long-term outcome in chronic heart failure: a data-based substudy of the EuroHeart Failure Survey. <i>European Journal of Heart Failure</i> , 2005, 7, 657-661.	7.1	32
20	Burden, treatment use, and outcome of secondary mitral regurgitation across the spectrum of heart failure: observational cohort study. <i>BMJ</i> , The, 2021, 373, n1421.	6.0	32
21	Bridging to heart transplantation: prostaglandin E1 versus prostacyclin versus dobutamine. <i>Journal of Heart and Lung Transplantation</i> , 1999, 18, 358-366.	0.6	31
22	Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 742-761.	1.9	31
23	A comparison of NT-proBNP and albuminuria for predicting cardiac events in patients with diabetes mellitus. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 944-951.	1.8	29
24	Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 927-943.	7.1	29
25	GDF-15 Is Associated with Cancer Incidence in Patients with Type 2 Diabetes. <i>Clinical Chemistry</i> , 2016, 62, 1612-1620.	3.2	26
26	Principal Morphomic and Functional Components of Secondary Mitral Regurgitation. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 2288-2300.	5.3	26
27	Incidence of normal values of natriuretic peptides in patients with chronic heart failure and impact on survival: A direct comparison of N-terminal atrial natriuretic peptide, N-terminal brain natriuretic peptide and brain natriuretic peptide. <i>European Journal of Heart Failure</i> , 2005, 7, 552-556.	7.1	24
28	Renin-Angiotensin System Fingerprints of Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2912-2914.	2.8	24
29	Increased resting heart rate and prognosis in treatment-naïve unselected cancer patients: results from a prospective observational study. <i>European Journal of Heart Failure</i> , 2020, 22, 1230-1238.	7.1	23
30	The inflammation-based modified Glasgow prognostic score is associated with survival in stable heart failure patients. <i>ESC Heart Failure</i> , 2020, 7, 654-662.	3.1	23
31	Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1577-1596.	7.1	23
32	Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112169.	5.6	22
33	Cardiac remodelling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 944-958.	7.1	22
34	Papillary Muscle Dyssynchrony-Mediated Functional Mitral Regurgitation. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1728-1737.	5.3	21
35	Functional capillary impairment in patients with ventricular assist devices. <i>Scientific Reports</i> , 2019, 9, 5909.	3.3	21
36	Liver-specific microRNA-122 as prognostic biomarker in patients with chronic systolic heart failure. <i>International Journal of Cardiology</i> , 2020, 303, 80-85.	1.7	21

#	ARTICLE	IF	CITATIONS
37	Performance of the recommended ESC/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2021, 20, 34.	6.8	20
38	Impaired High-Density Lipoprotein Anti-Oxidative Function Is Associated With Outcome in Patients With Chronic Heart Failure. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	19
39	Clusterin/apolipoprotein J is independently associated with survival in patients with chronic heart failure. <i>Journal of Clinical Lipidology</i> , 2017, 11, 178-184.	1.5	19
40	Longitudinal analysis of microvascular perfusion and neurodegenerative changes in early type 2 diabetic retinal disease. <i>British Journal of Ophthalmology</i> , 2022, 106, 528-533.	3.9	19
41	Natural Course of Nonsevere Secondary Tricuspid Regurgitation. <i>Journal of the American Society of Echocardiography</i> , 2021, 34, 13-19.	2.8	19
42	The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients. <i>Scientific Reports</i> , 2019, 9, 2554.	3.3	18
43	Myocardial Angiotensin Metabolism in End-Stage Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1731-1743.	2.8	18
44	Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles. <i>Heart</i> , 2016, 102, 1544-1551.	2.9	15
45	Subclinical involvement of the liver is associated with prognosis in treatment naïve cancer patients. <i>Oncotarget</i> , 2017, 8, 81250-81260.	1.8	15
46	Parameters associated with therapeutic response using peritoneal dialysis for therapy refractory heart failure and congestive right ventricular dysfunction. <i>PLoS ONE</i> , 2018, 13, e0206830.	2.5	14
47	Release of mitochondrial DNA is associated with mortality in severe acute heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 419-428.	1.0	14
48	Non-occlusive mesenteric ischaemia in out of hospital cardiac arrest survivors. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 450-458.	1.0	13
49	Increased concentrations of bioactive adrenomedullin subsequently to angiotensin-receptor/neprilysin-inhibitor treatment in chronic systolic heart failure. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 916-924.	2.4	13
50	Acute HIV Infection Results in Subclinical Inflammatory Cardiomyopathy. <i>Journal of Infectious Diseases</i> , 2018, 218, 466-470.	4.0	12
51	Inflammation-Based Scores as a Common Tool for Prognostic Assessment in Heart Failure or Cancer. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 725903.	2.4	12
52	Malnutrition outweighs the effect of the obesity paradox. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1477-1486.	7.3	12
53	What do patients with heart failure die from? A single assassin or a conspiracy?. <i>European Journal of Heart Failure</i> , 2020, 22, 26-28.	7.1	11
54	NT-proBNP as a means of triage for the risk of hospitalisation in primary care. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 55-61.	1.8	10

#	ARTICLE	IF	CITATIONS
55	Prognostic utility of the Seattle Heart Failure Score and amino terminal pro B-type natriuretic peptide in varying stages of systolic heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 533-538.	0.6	10
56	Phenotyping progression of secondary mitral regurgitation in chronic systolic heart failure. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13159.	3.4	10
57	GDF-15 in solid vs non-solid treatment-naïve malignancies. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13168.	3.4	10
58	Predictive power of the fractalkine receptor CX3CR1 on CD4 T cells in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2014, 171, 96-97.	1.7	9
59	Natural history of bivalvular functional regurgitation. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 565-573.	1.2	9
60	Heart Failure With Reduced Ejection Fraction Is Characterized by Systemic NEP Downregulation. <i>JACC Basic To Translational Science</i> , 2020, 5, 715-726.	4.1	9
61	Sacubitril/valsartan is well tolerated in patients with longstanding heart failure and history of cancer and improves ventricular function: real-world data. <i>Cardio-Oncology</i> , 2021, 7, 35.	1.7	9
62	Guideline directed medical therapy and reduction of secondary mitral regurgitation. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 755-764.	1.2	9
63	N-terminal B-type natriuretic peptide (NT-proBNP) is associated with disease severity in multiple myeloma. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12905.	3.4	8
64	Impaired High-Density Lipoprotein Anti-Oxidant Function Predicts Poor Outcome in Critically Ill Patients. <i>PLoS ONE</i> , 2016, 11, e0151706.	2.5	8
65	Neutrophil Activation/Maturation Markers in Chronic Heart Failure with Reduced Ejection Fraction. <i>Diagnostics</i> , 2022, 12, 444.	2.6	8
66	Heart failure disease management programs in Austria 2019. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 310-321.	1.9	7
67	Outcome of conservative management vs. assist device implantation in patients with advanced refractory heart failure. <i>European Journal of Clinical Investigation</i> , 2016, 46, 34-41.	3.4	6
68	B-type natriuretic peptide increases cortisol and catecholamine concentrations in healthy subjects. <i>Journal of Applied Physiology</i> , 2017, 122, 1249-1254.	2.5	6
69	The Prognostic Impact of Circulating Regulatory T Lymphocytes on Mortality in Patients with Ischemic Heart Failure with Reduced Ejection Fraction. <i>Mediators of Inflammation</i> , 2020, 2020, 1-7.	3.0	6
70	Neprilysin as a Biomarker: Challenges and Opportunities. <i>Cardiac Failure Review</i> , 2020, 6, e23.	3.0	6
71	Global regurgitant volume: approaching the critical mass in valvular-driven heart failure. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 21, 168-174.	1.2	5
72	Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF. <i>Journal of the American Heart Association</i> , 2020, 9, e015071.	3.7	5

#	ARTICLE	IF	CITATIONS
73	Impact of HIV infection and antiretroviral treatment on N-terminal prohormone of brain natriuretic peptide as surrogate of myocardial function. <i>Aids</i> , 2017, 31, 395-400.	2.2	5
74	Relevance of Neutrophil Neprilysin in Heart Failure. <i>Cells</i> , 2021, 10, 2922.	4.1	5
75	Increased granulocyte membrane neprilysin (CD10) expression is associated with better prognosis in heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 537-539.	7.1	4
76	Secondary mitral regurgitation—Insights from microRNA assessment. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13381.	3.4	4
77	Reply. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1845-1847.	2.8	3
78	Neprilysin inhibition does not alter dynamic of proenkephalin-119 and pro-substance P in heart failure. <i>ESC Heart Failure</i> , 2021, 8, 2016-2024.	3.1	3
79	Research update for articles published in <i>EJCI</i> in 2011. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1097-1110.	3.4	2
80	Prescription Bias in the Treatment of Chronic Systolic Heart Failure. <i>Annals of Internal Medicine</i> , 2020, 172, 70.	3.9	2
81	Soluble neprilysin and survival in critically ill patients. <i>ESC Heart Failure</i> , 2022, , .	3.1	2
82	Circulating dipeptidyl peptidase (cDPP3)—A marker for end-stage heart failure?. <i>Journal of Internal Medicine</i> , 2022, 291, 886-890.	6.0	2
83	Transcatheter Versus Surgical Valve Repair in Patients with Severe Mitral Regurgitation. <i>Journal of Personalized Medicine</i> , 2022, 12, 90.	2.5	2
84	Relationship of diabetes, heart failure, and N-terminal pro-B-type natriuretic peptide with cardiovascular outcomes in patients with atrial fibrillation. <i>ESC Heart Failure</i> , 2022, , .	3.1	2
85	Research update for articles published in <i>EJCI</i> in 2010. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1149-1164.	3.4	1
86	Comment on Hillis et al. The Relative and Combined Ability of High-Sensitivity Cardiac Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Cardiovascular Events and Death in Patients With Type 2 Diabetes. <i>Diabetes Care</i> 2014;37:295–303. <i>Diabetes Care</i> , 2014, 37, e152-e153.	8.6	1
87	An Integrated Imaging and Circulating Biomarker Approach for Secondary Tricuspid Regurgitation. <i>Journal of Personalized Medicine</i> , 2020, 10, 233.	2.5	1
88	Heart transplantation in Vienna: 25 years of experience. <i>Wiener Klinische Wochenschrift</i> , 2008, 120, 3-10.	1.9	0
89	EXAMINE: targeting risk and treatment in diabetes. <i>Lancet</i> , The, 2015, 386, 1444-1445.	13.7	0
90	Curriculum heart failure. <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 299-312.	1.9	0

#	ARTICLE	IF	CITATIONS
91	Current Insights Into Secondary Mitral Regurgitationâ€™ Workup and Management. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 1.	0.9	0
92	The Authors Reply:. JACC: Cardiovascular Imaging, 2020, 13, 891.	5.3	0